CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals Apr 13, 2020 8:00am EDT
CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates for a Range of Viruses including Coronavirus for International Markets Mar 23, 2020 8:00am EDT
CNS Pharmaceuticals Announces Business Highlights and 2019 Fourth Quarter Financial Results Mar 12, 2020 4:05pm EDT
CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020 Mar 05, 2020 4:05pm EST
CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains Cancer Free Mar 03, 2020 8:00am EST
CNS Pharmaceuticals Announces Collaboration with European Partner to Expand Clinical Trials to Pediatric Brain Tumors Feb 11, 2020 8:00am EST
CNS Pharmaceuticals Completes Pilot Manufacturing Steps Pursuant to FDA Pre-IND Guidance Jan 28, 2020 8:00am EST
CNS Pharmaceuticals Announces Contract with International GMP Manufacturer for Production of Berubicin Jan 14, 2020 8:00am EST
